Thomas Miller

Thomas Miller is a seasoned professional in the field of cancer research and biotechnology, currently serving as Principal Investigator at Institut Paoli-Calmettes since June 2019 and as a Research Collaborator at the National Cancer Institute (NCI) since October 2014. As a co-founder and COO of Paradigm Shift Therapeutics since September 2014, Thomas Miller has played a pivotal role in advancing therapeutic developments. Previous experience includes serving as Lead Scientist at Meso Scale Discovery, where responsibilities included developing preclinical assays for oncology drug discovery and managing external relationships. Thomas Miller has also contributed to significant research at NCI as a Cancer Research Fellow, with notable discoveries in the role of hydrogen sulfide in inflammation and tumor immunotherapy. Educational credentials include a PhD in Inorganic Chemistry from UCLA and a BS in Chemistry from the University of Pittsburgh.